Back to News
Market Impact: 0.2
Natera, TransCode Target Residual Colorectal Cancer With Trial Collaboration
Source: Nasdaq
Healthcare & Biotech
Natera and TransCode Therapeutics entered a strategic collaboration to support patient enrollment in TransCode’s Phase 2a trial of TTX-MC138 in colorectal cancer. The announcement provides no enrollment targets, financial terms, or trial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
NTRA0.35
RNAZ0.45
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital IQ Alternatives for Research and Deal Work
- Research Workflows, Report Format Selection, and Interactive Synthesis